There is increasing interest in using treatment breaks to reduce side effects without affecting outcomes. This phase 3 trial (STAR) was designed to see how a break in tyrosine kinase inhibitor (TKI) treatment compared to standard first-line treatment with TKIs for people with advanced renal cell carcinoma (RCC). Overall survival time and economic evaluation (quality […]
Pazopanib is used for first-line metastatic RCC treatment, but the data for poor-risk patients are scarce. The FLIPPER study was designed to determine the safety and efficacy of first-line pazopanib in poor-risk patients with metastatic RCC. FLIPPER was a single-arm, open-label, phase IV trial involving 60 patients with poor-risk metastatic mRCC. All patients were treated […]
A recent post hoc analysis of the results from the COMPARZ clinical trial, which compared first-line treatment with pazopanib versus sunitinib for metastatic renal cell carcinoma (RCC), was published in Clinical Genitourinary Cancer last February 2020. During the COMPARZ study, pazopanib and sunitinib (VEGF-TKI targeted therapy) had similar efficacy. However, this analysis showed that the […]
A recent literature review and network meta-analysis of phase 2/3 randomised, controlled clinical trials of approved first-line tyrosine kinase inhibitors (TKIs) involving more than 4,200 patients with metastatic renal cell carcinoma (RCC) has shown that cabozantinib, sunitinib, pazopanib, and tivozanib have similar efficacy, but tivozanib’s safety profile is superior to the profiles of the other […]
A retrospective study of the use of targeted therapies for advanced renal cell carcinoma (RCC) in war veterans in the USA reported poorer overall survival outcomes than those from clinical trials, as well as shorter treatment durations for first-line therapies with more frequent adverse events, dose reductions, and drug discontinuations. The study was published in […]
A study published in Clinical Genitourinary Cancer last month describes the real world clinical outcomes of treating advanced renal cell carcinoma (RCC) patients with pazopanib after they had already been treated with immunotherapy. A total of 258 patients were enrolled in the study and had been treated with immunotherapy before pazopanib as follows: nivolumab (68%), […]
Non-clear cell renal cell carcinoma (RCC) and sarcomatoid renal cell carcinoma are often treated similarly to clear cell RCC with the tyrosine kinase inhibitors, sunitinib and pazopanib. A recent study investigated the effectiveness of these two drugs for the first-line treatment of metastatic non-clear cell and sarcomatoid RCC. Of the 53 patients included in the […]
The following video interview with Dr Elizabeth Plimack from the Fox Chase Cancer Center in Philadelphia, USA discusses the results from a study that assessed the outcome of metastasectomy in patients with metastatic renal cell carcinoma (RCC). The study looked at patients with slow growing disease, and maybe one metastasis that was removed with surgery. […]
In this phase III study, presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago this week, the use of treatment with pazopanib after surgery to remove renal cell carcinoma (RCC) metastases (metastasectomy) was investigated. One hundred and twenty-nine patients with no evidence of disease after surgery to remove RCC metastases […]
Using gene profiling, a recent study published in Cancer Discovery has identified four distinct molecular subgroups associated with response to treatment with sunitinib or pazopanib and survival. The findings demonstrate the effects of the presence of immune cells and angiogenesis on the effectiveness of sunitinib and pazopanib against the cancer, and are important for individualised decision-making. […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
